Bright Minds Biosciences (DRUG) Free Cash Flow (2019 - 2026)

Bright Minds Biosciences (DRUG) has 7 years of Free Cash Flow data on file, last reported at -$6.7 million in Q1 2026.

• Quarterly Free Cash Flow fell 498.9% year-over-year to -$6.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.0 million (down 9572.95% YoY) and the FY2025 annual result came in at -$6.3 million, down 365.66% from the prior year.
• Free Cash Flow eased to -$6.7 million in Q1 2026, from -$4.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $2.9 million in Q1 2022 to a low of -$19.2 million in Q3 2022.
• A 5-year average of -$2.2 million and a median of $597467.2 in 2024 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 182.9% in 2025, down 4562.31% in 2025.
• Tracing DRUG's Free Cash Flow over 5 years: stood at $2.0 million in 2022, then sank by 69.23% to $603852.1 in 2023, then surged by 77.16% to $1.1 million in 2024, then sank by 489.85% to -$4.2 million in 2025, then slumped by 61.67% to -$6.7 million in 2026.
• The last three Free Cash Flow figures came in at -$6.7 million (Q1 2026), -$4.2 million (Q4 2025), and -$921379.0 (Q3 2025), per Business Quant data.